Recent News

• 04.14.2025 - Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
• 04.14.2025 - Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
• 04.01.2025 - Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
• 04.01.2025 - Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
• 03.25.2025 - Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• 03.25.2025 - Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• 03.10.2025 - Q4 2024 Coherus BioSciences, Inc. Earnings Conference Call
• 03.10.2025 - Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
• 03.10.2025 - Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
• 03.04.2025 - 45th Annual TD Cowen Health Care Conference

Recent Filings

• 04.01.2025 - EX-99.1 EX-99.1
• 04.01.2025 - 8-K Current report
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - 8-K Current report
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 8-K Current report
• 03.04.2025 - 8-K Current report
• 03.04.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material